These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Guanidino compounds and aliphatic monoamines in acute and chronic renal failure]. Suzuki Y. Nihon Jinzo Gakkai Shi; 1992 Oct; 34(10):1077-85. PubMed ID: 1289608 [Abstract] [Full Text] [Related]
24. Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes. Eloot S, Torremans A, De Smet R, Marescau B, De Deyn PP, Verdonck P, Vanholder R. Am J Kidney Dis; 2007 Aug; 50(2):279-88. PubMed ID: 17660029 [Abstract] [Full Text] [Related]
27. Potential role of middle molecular compounds in the development of uremic anemia. Leber HW, Debus E, Grulich U, Schütterle G. Artif Organs; 1981 Aug; 4 Suppl():63-7. PubMed ID: 7295098 [Abstract] [Full Text] [Related]
29. Inhibitors of erythroid colony-forming cells (CFU-E and BFU-E) in sera of azotemic patients with anemia of renal disease. Ohno Y, Rege AB, Fisher JW, Barona J. J Lab Clin Med; 1978 Dec; 92(6):916-23. PubMed ID: 739170 [Abstract] [Full Text] [Related]
30. Recent progress in the analysis of uremic toxins by mass spectrometry. Niwa T. J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Sep 01; 877(25):2600-6. PubMed ID: 19083276 [Abstract] [Full Text] [Related]
33. Effect of polyamines, methylguanidine, and guanidinosuccinic acid on calcitriol synthesis. Patel S, Hsu CH. J Lab Clin Med; 1990 Jan 01; 115(1):69-73. PubMed ID: 2299258 [Abstract] [Full Text] [Related]
34. Relationship between uremic toxins and oxidative stress in patients with chronic renal failure. Rutkowski P, Słominska EM, Szołkiewicz M, Aleksandrowicz E, Smolenski RT, Wołyniec W, Renke M, Wisterowicz K, Swierczynski J, Rutkowski B. Scand J Urol Nephrol; 2007 Jan 01; 41(3):243-8. PubMed ID: 17469035 [Abstract] [Full Text] [Related]
35. Uremic encephalopathy. Moe SM, Sprague SM. Clin Nephrol; 1994 Oct 01; 42(4):251-6. PubMed ID: 7834918 [Abstract] [Full Text] [Related]
36. Fast atom bombardment mass spectrometric determination of the molecular weight range of uremic compounds that displace phenytoin from protein binding: absence of midmolecular uremic toxins. Dasgupta A, Malik S. Am J Nephrol; 1994 Oct 01; 14(3):162-8. PubMed ID: 7977474 [Abstract] [Full Text] [Related]
37. [Uremic encephalopathy and oligo-elements]. Balestri PL. Clin Ter; 1995 Mar 01; 146(3):221-6. PubMed ID: 7789085 [Abstract] [Full Text] [Related]
38. Energy production and utilization by human platelets in the presence of some guanidines and phenols (uremic toxins) that inhibit aggregation. Carroll HJ. Thromb Diath Haemorrh; 1975 Sep 30; 34(1):63-71. PubMed ID: 1188836 [Abstract] [Full Text] [Related]
39. Potential uremic toxins modulate energy metabolism of cardiac myocytes in vitro. Weisensee D, Schnaars Y, Schoeppe W, Bereiter-Hahn J, Löw-Friedrich I. Exp Nephrol; 1997 Sep 30; 5(3):194-200. PubMed ID: 9208278 [Abstract] [Full Text] [Related]
40. Middle molecular weight substances in the cerebrospinal fluid of uremic patients. Sperschneider H, Spustova V, Stein G, Dzurik R. Clin Nephrol; 1982 Jun 30; 17(6):298-302. PubMed ID: 7105504 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]